tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

RVTYRevvity

Health care · Lab Instruments · NYSE
RVTY quote by TradingView
Compare with peers → Embed
FY2025 at a glance

Sales up 3.7%, free cash flow down to $509.4M

XBRL, from each 10-K
RevenueStatements ↓
$2.9B
from $2.8B in FY2024
FY2016FY2025
Net incomeStatements ↓
$241.2M
from $270.4M in FY2024
FY2016FY2025
Free cash flowStatements ↓
$509.4M
from $541.7M in FY2024
FY2016FY2025
EPS (diluted)Statements ↓
$2.07
from $2.20 in FY2024
FY2016FY2025
Operating marginStatements ↓
12.5%
from 12.6% in FY2024
FY2016FY2025
Total debtStatements ↓
$3.2B
from $3.2B in FY2024
FY2016FY2025
Price and key numbers

The latest figures

All key numbers (41, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)2.08Sales (ttm)2.9BNet income (ttm)237.6MSales growth+3.7%EPS growth-5.9%Sales Q/Q+1.3%
Free cash flow558.1MGross margin-Oper. margin12.3%Net margin8.2%FCF margin19.2%ROE3.3%
ROA2.0%R&D / sales7.6%Dividend0.28Debt/Eq0.44Curr. ratio1.80Cash1.0B
Op. cash flow (ttm)627.6MEBITDA762.0MEBITDA margin26.7%Net debt2.2BQuick ratio1.50Interest cover3.87
ROIC3.1%Payout ratio13.5%Tax rate10.6%Stock pay / sales0.8%Shares out.111.6MShares Y/Y-5.1%
Book / share64.78Cash / share9.17Sales / share26.09Asset turnover0.24Days sales out.95Sales 3Y CAGR-4.8%
Sales 5Y CAGR-5.5%EPS 3Y CAGR-22.9%EPS 5Y CAGR-20.5%Employees11,000Sales / employee265K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

RVTY against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
RVTYPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+3.7%45th of 60 · median +7.1%
Net margin
8.2%34th of 60 · median 9.6%
Return on equity
3.3%46th of 54 · median 13.1%
Free cash flow margin
19.2%20th of 56 · median 15.5%
Debt / equity (less is better)
0.4413th of 49 · median 0.66
RVTY and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
RVTY Revvity$2.9B +3.7%-8.2%3.3%19.2%0.44
CRL Charles River Laboratories$4.0B -0.9%-1.0%1.2%10.0%0.76
VEEV Veeva Systems$3.5B +16.3%75.0%29.3%13.7%--
WST West Pharmaceutical Services$3.4B +6.3%37.6%18.8%21.5%13.3%0.07
PODD Insulet Corporation$3.2B +30.7%71.9%13.4%27.1%8.2%0.61
MRNA Moderna$2.5B -39.9%28.0%-110.5%-40.8%-78.0%0.09
Where each dollar goes

From $3.8B of sales to $943.2M of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $2.4BRevenue to Cost of revenue: $1.4BGross profit to Operating profit: $1.3BGross profit to Operating expenses: $1.2BOperating profit to Net profit: $943.2MOperating profit to Tax: $315.3MOperating expenses to R&D: $200.3MOperating expenses to SG&A: $975.2M Revenue: $3.8B Revenue$3.8B +1% Y/Y Gross profit: $2.4B · 64% margin Gross profit$2.4B64% margin +15% Y/Y Cost of revenue: $1.4B · 36% of revenue Cost of revenue$1.4B36% of revenue Operating profit: $1.3B · 33% margin Operating profit$1.3B33% margin +45% Y/Y Operating expenses: $1.2B · 31% of revenue Operating expenses$1.2B31% of revenue Net profit: $943.2M · 25% margin Net profit$943.2M25% margin +30% Y/Y Tax: $315.3M · 8% of revenue Tax$315.3M8% of revenue R&D: $200.3M · 5% of revenue R&D$200.3M5% of revenue SG&A: $975.2M · 25% of revenue SG&A$975.2M25% of revenue

Swipe sideways for the whole flow →

From $3.3B of sales to $569.2M of profit

FY2022, from the 10-K income statement and revenue by product
Product to Revenue: $2.6BService to Revenue: $677.2MRevenue to Gross profit: $2.0BRevenue to Cost of revenue: $1.3BGross profit to Operating profit: $742.7MGross profit to Operating expenses: $1.2BOperating profit to Net profit: $569.2MOperating profit to Tax & other: $173.5MOperating expenses to R&D: $221.6MOperating expenses to SG&A: $1.0B Product: $2.6B · 80% Product$2.6B80% Service: $677.2M · 20% Service$677.2M20% Revenue: $3.3B Revenue$3.3B −13% Y/Y Gross profit: $2.0B · 60% margin Gross profit$2.0B60% margin −18% Y/Y Cost of revenue: $1.3B · 40% of revenue Cost of revenue$1.3B40% of revenue Operating profit: $742.7M · 22% margin Operating profit$742.7M22% margin −41% Y/Y Operating expenses: $1.2B · 38% of revenue Operating expenses$1.2B38% of revenue Net profit: $569.2M · 17% margin Net profit$569.2M17% margin −40% Y/Y Tax & other: $173.5M · 5% of revenue Tax & other$173.5M5% of revenue R&D: $221.6M · 7% of revenue R&D$221.6M7% of revenue SG&A: $1.0B · 31% of revenue SG&A$1.0B31% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

1 of 3
  • !
    Net margin below the peer median8.2% vs 9.6%
  • !
    Return on equity below 15%3.3%
  • ✓
    A profit in every one of 10 years
Net margin, FY2016 to FY2025: 11.1% → 8.4%

Balance sheet

2 of 4
  • !
    Interest covered less than 5 timesOperating income is 3.9× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.44 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 1.80
  • !
    Net debt over 3 years of free cash flow$2.2B net debt, 3.9 years
Debt / equity at each year end, FY2016 to FY2025: 0.49 → 0.44
What the debt is made of ↓

Cash and shareholders

2 of 4
  • ✓
    Free cash flow positive in every one of 10 years$509.4M last year
  • !
    Share count up over 5 years+4.0%
  • !
    Dividend per share not up over 5 years$0.28 → $0.28
  • ✓
    Cash from operations above net income$582.9M vs $241.2M
Free cash flow, FY2016 to FY2025: 318.9M → 509.4M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Debt

$3.2B of principal due, schedule of Dec 28, 2025

Repayment schedule →

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Revenue and net income, FY2016 to FY2025

Revenue 2.9B Net income 241.2M
FY2016 revenue 2.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-19-000003 FY2016 net income 234.3M · NetIncomeLoss, 0000031791-19-000003 2.1B FY2016 FY2017 revenue 2.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-20-000003 FY2017 net income 292.6M · NetIncomeLoss, 0000031791-20-000003 2.3B FY2017 FY2018 revenue 2.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-21-000003 FY2018 net income 237.9M · NetIncomeLoss, 0000031791-21-000003 2.8B FY2018 FY2019 revenue 2.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-22-000003 FY2019 net income 227.6M · NetIncomeLoss, 0000031791-22-000003 2.9B FY2019 FY2020 revenue 3.8B · Revenues, 0000031791-21-000003 FY2020 net income 727.9M · NetIncomeLoss, 0000031791-23-000004 3.8B FY2020 FY2021 revenue 3.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-24-000004 FY2021 net income 943.2M · NetIncomeLoss, 0000031791-24-000004 3.8B FY2021 FY2022 revenue 3.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-25-000009 FY2022 net income 569.2M · NetIncomeLoss, 0000031791-25-000009 3.3B FY2022 FY2023 revenue 2.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-26-000012 FY2023 net income 693.1M · NetIncomeLoss, 0000031791-26-000012 2.8B FY2023 FY2024 revenue 2.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-26-000012 FY2024 net income 270.4M · NetIncomeLoss, 0000031791-26-000012 2.8B FY2024 FY2025 revenue 2.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000031791-26-000012 FY2025 net income 241.2M · NetIncomeLoss, 0000031791-26-000012 2.9B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

Statements

Income statement, balance sheet and cash flow

XBRL, each 10-K and 10-Q

RVTY's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue2.9B
FY2016: 2.1BFY2017: 2.3BFY2018: 2.8BFY2019: 2.9BFY2020: 3.8BFY2021: 3.8BFY2022: 3.3BFY2023: 2.8BFY2024: 2.8BFY2025: 2.9B FY2017FY2019FY2021FY2023FY2025
Net income241.2M
FY2016: 234.3MFY2017: 292.6MFY2018: 237.9MFY2019: 227.6MFY2020: 727.9MFY2021: 943.2MFY2022: 569.2MFY2023: 693.1MFY2024: 270.4MFY2025: 241.2M FY2017FY2019FY2021FY2023FY2025
Free cash flow509.4M
FY2016: 318.9MFY2017: 249.4MFY2018: 217.8MFY2019: 287.1MFY2020: 828.5MFY2021: 1.3BFY2022: 594.2MFY2023: 9.9MFY2024: 541.7MFY2025: 509.4M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)2.07
FY2016: 2.12FY2017: 2.64FY2018: 2.13FY2019: 2.04FY2020: 6.49FY2021: 8.08FY2022: 4.50FY2023: 5.55FY2024: 2.20FY2025: 2.07 FY2017FY2019FY2021FY2023FY2025
Dividend per share0.28
FY2016: 0.28FY2017: 0.28FY2018: 0.28FY2019: 0.28FY2020: 0.28FY2021: -FY2022: 0.28FY2023: 0.28FY2024: 0.28FY2025: 0.28 FY2017FY2019FY2021FY2023FY2025
Diluted shares116.6M
FY2016: 110.3MFY2017: 110.9MFY2018: 111.5MFY2019: 111.5MFY2020: 112.1MFY2021: 116.7MFY2022: 126.4MFY2023: 124.8MFY2024: 122.8MFY2025: 116.6M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 28, 2025
RevenueSharevs year before
Life Sciences 1.4B50.1% +2.3%
Diagnostics 1.4B49.9% +5.1%

10-K 0000031791-26-000012, segment and revenue notes (XBRL).

Revenue by product or service

year to Dec 28, 2025
RevenueSharevs year before
Product 2.4B83.7% +2.2%
Service 466.1M16.3% +11.8%

10-K 0000031791-26-000012, segment and revenue notes (XBRL).

Revenue by region

year to Dec 28, 2025
RevenueSharevs year before
Americas 1.3B44.0% +2.7%
UNITED STATES 1.1B39.4% +2.6%
Other International 1.0B35.0% +7.4%
Europe 825.0M28.9% +11.1%
Asia 775.1M27.1% -1.8%
CHINA 425.1M14.9% -5.5%
GERMANY 177.7M6.2% +9.3%
UNITED KINGDOM 126.8M4.4% +12.4%

10-K 0000031791-26-000012, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue2.1B2.3B2.8B2.9B3.8B3.8B3.3B2.8B2.8B2.9B
Cost of revenue664.8M708.7M1.4B-------
Gross profit1.0B1.1B1.3B1.4B2.1B2.4B2.0B---
R&D124.2M139.5M194.0M189.3M146.4M200.3M221.6M216.6M196.8M215.8M
SG&A590.5M626.0M811.9M815.3M716.5M975.2M1.0B1.0B994.1M991.9M
Operating income294.6M295.6M323.9M362.0M867.3M1.3B742.7M300.6M346.7M356.6M
Interest expense41.5M43.9M67.0M63.6M49.7M54.1M104.0M98.8M96.3M92.2M
Pretax income244.1M296.7M257.7M237.1M800.1M1.2B651.8M183.0M316.1M268.3M
Income tax28.4M139.8M20.2M9.4M169.5M314.1M139.2M3.5M33.1M28.4M
Net income234.3M292.6M237.9M227.6M727.9M943.2M569.2M693.1M270.4M241.2M
EPS (diluted)2.122.642.132.046.498.084.505.552.202.07
Diluted shares110.3M110.9M111.5M111.5M112.1M116.7M126.4M124.8M122.8M116.6M
Depreciation & amortization100.0M105.0M180.6M214.0M201.6M311.4M427.0M431.8M427.8M405.3M
EBITDA394.6M400.6M504.5M576.0M1.1B1.6B1.2B732.3M774.6M762.0M
Gross margin47.9%47.6%48.3%48.4%55.8%63.6%60.1%---
Operating margin13.9%13.1%11.7%12.6%22.9%32.9%22.4%10.9%12.6%12.5%
Net margin11.1%13.0%8.6%7.9%19.2%24.6%17.2%25.2%9.8%8.4%
Revenue growth-+6.7%+23.1%+3.8%+31.2%+1.2%-13.5%-16.9%+0.2%+3.7%
EPS growth-+24.5%-19.3%-4.2%+218%+24.5%-44.3%+23.3%-60.4%-5.9%

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash359.3M202.1M163.1M191.9M387.1M603.3M454.4M913.2M1.2B919.9M
Short-term investments------0689.9M0-
Receivables425.6M552.3M632.7M725.2M1.2B707.9M612.8M632.8M632.4M744.7M
Inventory246.8M351.7M338.3M356.9M514.6M425.9M405.5M428.1M367.6M379.5M
Current assets1.2B1.2B1.2B1.4B2.2B2.4B3.3B3.0B2.3B2.2B
Property & equipment145.5M298.1M318.6M318.2M368.3M485.5M482.9M509.7M482.2M479.2M
Goodwill2.2B3.0B3.0B3.1B2.6B6.6B6.5B6.5B6.5B6.6B
Total assets4.3B6.1B6.0B6.5B8.0B15.0B14.1B13.6B12.4B12.2B
Accounts payable168.0M222.1M220.9M235.9M327.3M324.8M272.8M204.1M167.5M185.5M
Current liabilities603.4M950.9M771.6M762.8M1.7B1.2B1.5B1.5B653.1M1.3B
Total debt1.0B2.0B1.9B2.1B2.0B5.0B4.4B3.9B3.2B3.2B
Total liabilities2.1B3.6B3.4B3.7B4.2B7.9B6.7B5.7B4.7B4.9B
Shareholders' equity2.2B2.5B2.6B2.8B3.7B7.1B7.4B7.9B7.7B7.3B
Retained earnings2.1B2.4B2.6B2.8B3.5B4.4B5.0B5.6B5.8B6.1B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow350.6M288.5M311.0M363.5M892.2M1.4B679.8M91.3M628.3M582.9M
Capital spending31.7M39.1M93.3M76.3M63.6M86.0M85.6M81.4M86.6M73.5M
Free cash flow318.9M249.4M217.8M287.1M828.5M1.3B594.2M9.9M541.7M509.4M
Stock-based pay (added back)17.2M25.4M28.8M31.5M26.9M29.7M51.5M41.4M37.8M22.8M
Dividends paid30.8M30.8M31.0M31.1M31.2M32.4M35.3M35.0M34.5M32.8M
Buybacks151.8M3.8M57.4M6.3M6.9M73.1M80.6M388.9M369.6M820.8M
Debt raised546.2M0369.3M847.2M03.1B00--
Debt repaid-00530.3M0339.6M57.9M523.8M711.5M0
Investing cash flow-83.9M-1.3B-159.9M-487.6M-504.5M-4.1B-132.9M1.3B776.2M-17.4M
Financing cash flow-115.0M782.2M-179.2M-150.1M-202.9M2.9B-661.8M-947.1M-1.1B-857.5M
Dividend per share0.280.280.280.280.28-0.280.280.280.28

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)17.2M25.4M28.8M31.5M26.9M29.7M51.5M41.4M37.8M22.8M
Stock-based pay / revenue0.8%1.1%1.0%1.1%0.7%0.8%1.6%1.5%1.4%0.8%
Operating lease cost---61.2M37.6M39.5M40.0M47.7M41.0M47.9M
Operating lease cash paid---50.2M34.4M39.0M37.5M42.6M33.2M37.2M
Right-of-use assets--0167.3M207.2M164.0M188.4M155.1M167.7M165.4M
Operating lease liabilities--147.1M183.0M228.7M176.7M201.2M165.7M175.1M178.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Next Peers in numbers →